22 results for author:"Blaisdell J." in Literature citations
Results Customize
› Repeat search in UniProtKB (15)
| CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. Joy M.S., Dornbrook-Lavender K., Blaisdell J., Hilliard T., Boyette T., Hu Y., Hogan S.L., Candiani C., Falk R.J., Goldstein J.A. Eur. J. Clin. Pharmacol. 65:947-953(2009) · Mapped (8) |
| Discovery of new potentially defective alleles of human CYP2C9. Blaisdell J., Jorge-Nebert L.F., Coulter S., Ferguson S.S., Lee S.J., Chanas B., Xi T., Mohrenweiser H., Ghanayem B., Goldstein J.A. Pharmacogenetics 14:527-537(2004) · Mapped (7) |
| Cloning, expression, and characterization of three new mouse cytochrome p450 enzymes and partial characterization of their fatty acid oxidation activities. Wang H., Zhao Y., Bradbury J.A., Graves J.P., Foley J., Blaisdell J.A., Goldstein J.A., Zeldin D.C. Mol. Pharmacol. 65:1148-1158(2004) · UniProtKB (3) |
| Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. Lee C.R., Pieper J.A., Frye R.F., Hinderliter A.L., Blaisdell J.A., Goldstein J.A. Eur. J. Clin. Pharmacol. 58:791-794(2003) · Mapped (7) |
| Identification and functional characterization of new potentially defective alleles of human CYP2C19. Blaisdell J., Mohrenweiser H., Jackson J., Ferguson S., Coulter S., Chanas B., Xi T., Ghanayem B., Goldstein J.A. Pharmacogenetics 12:703-711(2002) · UniProtKB (1) |
| Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes. Lee C.R., Pieper J.A., Hinderliter A.L., Blaisdell J.A., Goldstein J.A. Clin. Pharmacol. Ther. 72:562-571(2002) · Mapped (7) |
| Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. Tassaneeyakul W., Tawalee A., Tassaneeyakul W., Kukongviriyapan V., Blaisdell J., Goldstein J.A., Gaysornsiri D. Pharmacogenetics 12:221-225(2002) · Mapped (3) |
| Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Kidd R.S., Curry T.B., Gallagher S., Edeki T., Blaisdell J., Goldstein J.A. Pharmacogenetics 11:803-808(2001) · Mapped (7) |
| Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Dai D., Zeldin D.C., Blaisdell J.A., Chanas B., Coulter S.J., Ghanayem B.I., Goldstein J.A. Pharmacogenetics 11:597-607(2001) · UniProtKB (1) |
| A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. Ibeanu G.C., Blaisdell J., Ferguson R.J., Ghanayem B.I., Brosen K., Benhamou S., Bouchardy C., Wilkinson G.R., Dayer P., Goldstein J.A. J. Pharmacol. Exp. Ther. 290:635-640(1999) · UniProtKB (1) |
| An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Ibeanu G.C., Blaisdell J., Ghanayem B.I., Beyeler C., Benhamou S., Bouchardy C., Wilkinson G.R., Dayer P., Daly A.K., Goldstein J.A. Pharmacogenetics 8:129-135(1998) · UniProtKB (1) |
| Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. Ibeanu G.C., Goldstein J.A., Meyer U.A., Benhamou S., Bouchardy C., Dayer P., Ghanayem B.I., Blaisdell J. J. Pharmacol. Exp. Ther. 286:1490-1495(1998) · UniProtKB (1) |
| Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid. Luo G., Zeldin D.C., Blaisdell J.A., Hodgson E., Goldstein J.A. Arch. Biochem. Biophys. 357:45-57(1998) · UniProtKB (4) · Mapped (10) |
| Isolation of a new canine cytochrome P450 cDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Blaisdell J., Goldstein J.A., Bai S.A. Drug Metab. Dispos. 26:278-283(1998) · UniProtKB (2) |
| Analysis of the mechanisms of action of the Saccharomyces cerevisiae dominant lethal cdc42G12V and dominant negative cdc42D118A mutations. Davis C.R., Richman T.J., Deliduka S.B., Blaisdell J.O., Collins C.C., Johnson D.I. J. Biol. Chem. 273:849-858(1998) · Mapped (5) |
| Escherichia coli endonuclease VIII: cloning, sequencing, and overexpression of the nei structural gene and characterization of nei and nei nth mutants. Jiang D., Hatahet Z., Blaisdell J.O., Melamede R.J., Wallace S.S. J. Bacteriol. 179:3773-3782(1997) · UniProtKB (1) |
| Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. Xiao Z.S., Goldstein J.A., Xie H.G., Blaisdell J., Wang W., Jiang C.H., Yan F.X., He N., Huang S.L., Xu Z.H. et al. J. Pharmacol. Exp. Ther. 281:604-609(1997) · UniProtKB (1) |
| Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. de Morais S.M., Schweikl H., Blaisdell J., Goldstein J.A. Biochem. Biophys. Res. Commun. 194:194-201(1993) · UniProtKB (3) |
| The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. de Morais S.M.F., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., Goldstein J.A. J. Biol. Chem. 269:15419-15422(1994) · UniProtKB (1) |
| No title Romkes M., Faletto M.B., Blaisdell J.A., Raucy J.L., Goldstein J.A. Biochemistry 32:1390-1390(1993) · UniProtKB (2) |
| Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. De Morais S.M.F., Wilkinson G.R., Blaisdell J., Meyer U.A., Nakamura K., Goldstein J.A. Mol. Pharmacol. 46:594-598(1994) · UniProtKB (1) |
| Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Romkes M., Faletto M.B., Blaisdell J.A., Raucy J.L., Goldstein J.A. Biochemistry 30:3247-3255(1991) · UniProtKB (5) |